...a medical meeting. Teva has exclusive, worldwide rights to the oral quinoline-3-carboxamide immunomodulator from Active. Active Biotech AB...
...atrophy Status: Phase II data Milestone: NA Chris Lieu Nerventra (Brand), 5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal) Active Biotech AB Teva...

...dipeptide cleaved from human serum albumin. The biotech ended the year valued at $309 million. Active Biotech AB...
...to treat Duchenne muscular dystrophy (DMD) caused by a nonsense mutation Companies and Institutions Mentioned Active Biotech AB...
...bellwethers.” BioCentury (2018) Cukier-Meisner, E. “Car dealing.” BioCentury (2018) Amran Gowani, Senior Editor, Research & Analytics Ampion ANB020 cabiralizumab CART-BCMA laquinimod LCAR-B38M Mongersen Opdivo PARP inhibior Yescarta Zejula Active Biotech AB Ampio...

...relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, May 12 ). Laquinimod is an oral quinoline-3-carboxamide immunomodulator. Active Biotech AB...
...of new T2 lesions and extended MRI data Status: Phase II data Milestone: NA Jaime De Leon laquinimod Nerventra SAIK-MS Active Biotech AB Teva...

...products being developed by partner Inspiration Biopharmaceuticals Inc. and prostate cancer therapy tasquinimod from partner Active Biotech AB...
...are expected to start Phase I testing in 2019 for spasticity. Companies and Institutions Mentioned Active Biotech AB...

...3 to treat RCC. Eight companies in the sub-$500 million band lost 70% or more. Active Biotech AB...
...quality of life, increased risk of infection and inadequate manufacturing controls Companies and Institutions Mentioned Active Biotech AB...
...Spring, Md. XBiotech Inc. (NASDAQ:XBIT), Austin, Texas Meredith Durkin Wolfe, Associate Editor, Research & Analytics eptinezumab Evenity indoximod Kevzara laquinimod Oral neratinib Pexa-Vec tivozanib vadastuximab talirine Xilonix Active Biotech AB Alder...

...was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB...

...and atherosclerotic lesion size. Next steps could include testing other S100A9 inhibitors in the models. Active Biotech AB...
...in Phase II testing for systemic lupus erythematosus (SLE) and Phase I for systemic sclerosis. Active Biotech AB...

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod...
...is continuing clinical studies of the product in primary progressive MS and Huntington's disease (HD). Active Biotech AB...
...time to CDP after ≥6 and ≥9 months Status: Phase III data Milestone: NA Jaime De Leon laquinimod SAIK-MS Active Biotech AB Teva...

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint...
...lost SEK0.40 to SEK17.70 on Friday. The partners announced CONCERTO's results after European market hours. Becky Simon laquinimod SAIK-MS Active Biotech AB Teva...

...keratosis Submit MAA Mid-2017 Acorda Therapeutics Inc. (NASDAQ:ACOR) CVT-301 Parkinson’s disease (PD) Submit NDA 2Q17 Active Biotech AB...